An observational study in Deep Vein Thrombosis of the Lower Extremities, sponsored by Rajaie Cardiovascular Medical and Research Center. Active, not recruiting at 1 site in Iran. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Rajaie Cardiovascular Medical and Research Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective single-arm cohort study aims to develop an AI-powered prediction model for treatment outcomes in patients with acute extensive iliofemoral deep vein thrombosis (IF-DVT) undergoing stent-free pharmacomechanical thrombolysis. The study addresses the current lack of validated tools for patient selection and outcome prediction in catheter-directed interventions for proximal DVT.
Thirty consecutive adult patients with MRV-confirmed acute IF-DVT will undergo pharmacomechanical thrombolysis using the AngioJet ZelanteDVT system with adjunctive rtPA administration.
The primary objective is to develop a convolutional neural network (CNN) trained on serial MRV imaging data to predict three-month venous recanalization success. MRV acquisitions occur at baseline, predischarge, and three-month follow-up. Ground truth segmentation will be performed by an experienced radiologist using 3D Slicer, with semi-automated propagation across the dataset. Feature extraction will include geometric metrics, radiomic texture analysis, and morphological characteristics of both thrombus and vessel architecture.
Secondary endpoints include acute kidney injury incidence (a significant concern with rheolytic thrombectomy due to hemolysis-induced nephrotoxicity), post-thrombotic syndrome development assessed via Villalta scoring, and various safety outcomes including major bleeding per ISTH criteria.
The study protocol incorporates rigorous monitoring for AKI using KDIGO criteria, with systematic evaluation of renal function, hemolysis markers, and electrolyte balance. Hydration protocols and nephroprotective measures will be standardized, though specific strategies require clarification from the nephrology team.
This research addresses critical gaps in evidence-based patient selection for invasive DVT treatment, particularly following the mixed results of the ATTRACT trial. The AI prediction model could enable personalized treatment decisions, potentially improving the risk-benefit ratio of pharmacomechanical interventions while reducing unnecessary procedures in patients unlikely to benefit.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
This study's enrollment of 30 is below the median of 301 across 274 observational studies indexed under Venous Thrombosis.
Browse Venous Thrombosis studies →Rajaie Cardiovascular Medical and Research Center is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be drawn from adult patients aged 18 years and older of both sexes presenting to the Rajaie Cardiovascular Medical and Research Institute, a tertiary referral cardiovascular center in Tehran, Iran, with acute symptomatic iliofemoral deep vein thrombosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with extensive ioliofemoral DVT candidate for pharmaco-mechanical thrombectomy
Device: Rheolytic thrombectomy
Rheolytic thrombectomy via AngioJet ZelanteDVTTM Catheter (Boston Scientific Co., USA).
During the procedure
The extent of venous recanalization after stent-free pharmacomechanical thrombolysis as assessed by magnetic resonance venography at three months post-procedure. Recanalization will be graded as: Grade 0 (no flow/complete occlusion), Grade 1 (minimal flow with ≤25% lumen patency), Grade 2 (partial flow with 26-75% patency), or Grade 3 (near-complete flow with \>75% patency). Treatment success is defined as achieving Grade 2 or 3 recanalization.
Time frame: 3 months post-procedure
MRV-based Predischarge Venous Recanalization
The extent of venous recanalization in the acute phase after stent-free pharmacomechanical thrombolysis as measured by magnetic resonance venography, classified as complete (\>90% clearance), nearly complete (50-90% clearance), or partial (\<50% resolution)
Time frame: At hospital discharge (typically 3-7 days post-procedure)
At hospital discharge (typically 3-7 days post-procedure)
Quantified thrombus volume reduction from baseline to three-month follow-up as measured by magnetic resonance venography, with meaningful reduction defined as ≥50% volume decrease
Time frame: 3 months post-procedure
MRV-based Predischarge Percentage Reduction in Thrombus Volume
Quantified thrombus volume reduction from baseline to hospital discharge as measured by magnetic resonance venography, with meaningful reduction defined as ≥50% volume decrease
Time frame: At hospital discharge (typically 3-7 days post-procedure)
Postprocedural Acute Kidney Injury Occurrence
Development of acute kidney injury during hospitalization based on KDIGO criteria: ≥0.3 mg/dL increase in serum creatinine within 48 hours, ≥1.5x baseline creatinine increase, or urine output \<0.5 mL/kg/h for 6 hours.
Time frame: During index hospitalization (typically 3-7 days)
Need for New Renal Replacement Therapy
Requirement for initiation of any form of renal replacement therapy (hemodialysis, continuous veno-venous hemofiltration, peritoneal dialysis) due to acute kidney injury in patients without previous dialysis history.
Time frame: During index hospitalization (typically 3-7 days)
Postprocedural Oliguria or Anuria
Development of oliguria (urine output \<0.5 mL/kg/hour) or anuria (urine output \<50 mL/day) during the index hospitalization period.
Time frame: During index hospitalization (typically 3-7 days)
Postprocedural Hyperkalemia
Elevated serum potassium concentration above normal limits (\>5.0-5.5 mEq/L) during the index hospitalization period.
Time frame: During index hospitalization (typically 3-7 days)
Postprocedural Gross Hematuria
Presence of visible blood in urine detected by visual inspection or urine testing during the index hospitalization period.
Time frame: During index hospitalization (typically 3-7 days)
Major Bleeding Events
Major bleeding according to International Society of Thrombosis and Haemostasis (ISTH) definition: fatal bleeding, bleeding in critical organs, or bleeding causing ≥2.0 g/dL hemoglobin decrease or requiring ≥2 units red blood cell transfusion.
Time frame: During index hospitalization (typically 3-7 days)
Three-month Recurrent Venous Thromboembolism
Objectively confirmed recurrent symptomatic venous thromboembolism (deep vein thrombosis or pulmonary embolism) during the three-month follow-up period.
Time frame: 3 months post-procedure
Three-month Post-thrombotic Syndrome Incidence
Development of post-thrombotic syndrome defined as Villalta score ≥5, assessed through standardized evaluation of symptoms (pain, cramps, heaviness, paresthesia, pruritus) and clinical signs (edema, induration, hyperpigmentation, redness, venous ectasia, calf pain on compression).
Time frame: 3 months post-procedure
Three-month Post-thrombotic Syndrome Severity
Severity classification of post-thrombotic syndrome using Villalta score: mild (5-9), moderate (10-14), or severe (≥15 or venous ulceration).
Time frame: 3 months post-procedure
In-hospital All-cause Mortality
Death from any cause during the index hospitalization period.
Time frame: During index hospitalization (typically 3-7 days)
Three-month All-cause Mortality
Death from any cause during the three-month follow-up period.
Time frame: 3 months post-procedure
Technical Success Rate
Successful placement of the AngioJet device catheter and initiation of the thrombectomy procedure as intended per protocol.
Time frame: During the procedure
Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.
Of 103 non-industry observational studies under Venous Thrombosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 99. This study's planned 15 months is below that.
Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rajaie Cardiovascular Medical and Research Center